Anıl UYSAL
Research Subjects
Anıl UYSAL has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Elif Erdem
1Çukurova University Faculty of Medicine, Department of Ophthalmology, Adana, Turkey
2 shared publications - Meltem Yağmur
1Çukurova University Faculty of Medicine, Department of Ophthalmology, Adana, Turkey
2 shared publications - Ebru Esen
Çukurova University
1 shared publication Hülya Bi̇nokay
ÇUKUROVA ÜNİVERSİTES
1 shared publicationİbRahim İnAn Harbi̇yEli̇
Cukurova Universitesi
1 shared publicationİbrahim İnan Harbi̇yeli̇
ÇUKUROVA ÜNİVERSİTES
1 shared publication
Latest Publications
- 28 July 2023
- Published by Springer Nature in International Ophthalmology
- Vol. 43 (11) , 4171-4180
Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
Purpose To compare the visual and anatomic outcomes of intravitreal ranibizumab versus aflibercept in patients with diabetic macular edema (DME) in a real-world study. Methods This is a single-center retrospective comparative study of treatment-naïve patients who received intravitreal ranibizumab or aflibercept administration for DME for at least 12 months on an as needed regimen following three-monthly loading doses. The primary outcomes of the study were the mean change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and central macular volume (CMV). Factors to potentially affect these parameters were also analyzed. Results A total of 100 eyes (66 patients) were included in the study. Fifty two eyes received ranibizumab and 48 eyes in aflibercept injections. At the end of follow-up, the improvement in mean BCVA was similar in both groups (p = 0.38). While the decrease in mean CMT at the 4th-month visit was significantly higher in the aflibercept-treated group than in the ranibizumab-treated group (p = 0.02), there was no difference between the two groups at the end of the 1-year follow-up (p = 0.25). There was no significant difference between the two groups in terms of change in mean CMV during the follow-up (p = 0.26, p = 0.27 at 4 and 12 months, respectively). The mean number of injections were also similar between groups (4.5 ± 1 vs. 4.6 ± 1.1 respectively, p = 0.63). Conclusion In a real-world setting, ranibizumab and aflibercept were both found to be effective in the first-line treatment of DME. Patients with DME who received fewer injections in the real-world could achieve visual and anatomical results comparable to randomized controlled trials participants.
- 28 July 2023
- Published by Springer Nature in International Ophthalmology
- Vol. 43 (11) , 4171-4180
Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
Purpose To compare the visual and anatomic outcomes of intravitreal ranibizumab versus aflibercept in patients with diabetic macular edema (DME) in a real-world study. Methods This is a single-center retrospective comparative study of treatment-naïve patients who received intravitreal ranibizumab or aflibercept administration for DME for at least 12 months on an as needed regimen following three-monthly loading doses. The primary outcomes of the study were the mean change in best-corrected visual acuity (BCVA), central macular thickness (CMT), and central macular volume (CMV). Factors to potentially affect these parameters were also analyzed. Results A total of 100 eyes (66 patients) were included in the study. Fifty two eyes received ranibizumab and 48 eyes in aflibercept injections. At the end of follow-up, the improvement in mean BCVA was similar in both groups (p = 0.38). While the decrease in mean CMT at the 4th-month visit was significantly higher in the aflibercept-treated group than in the ranibizumab-treated group (p = 0.02), there was no difference between the two groups at the end of the 1-year follow-up (p = 0.25). There was no significant difference between the two groups in terms of change in mean CMV during the follow-up (p = 0.26, p = 0.27 at 4 and 12 months, respectively). The mean number of injections were also similar between groups (4.5 ± 1 vs. 4.6 ± 1.1 respectively, p = 0.63). Conclusion In a real-world setting, ranibizumab and aflibercept were both found to be effective in the first-line treatment of DME. Patients with DME who received fewer injections in the real-world could achieve visual and anatomical results comparable to randomized controlled trials participants.
- Open Access
- 1 January 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (1) , 426-435
Evaluation of the biomechanical properties of the cornea in different glaucoma types with Corvis Scheimpflug technology
Purpose: The aim of this study was to evaluate the biomechanical properties of the cornea in different types of glaucoma and the relationship between corneal biomechanics and demographic and clinical parameters. Materials and Methods: Primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma (PEG) and pigmentary glaucoma (PG) cases and healthy subjects as a control group were included in this retrospective observational study. Detailed ophthalmological examination was performed, computerized perimetry and optical coherence tomography (OCT) data were recorded in all cases. Corneal biomechanical properties were evaluated with Corvis ST (R) (Oculus, Wetzlar, Germany). Results: Forty-eight glaucoma cases (25 POAG, 15 PEG, 8 PG; 48 eyes) with a mean age of 61.4 +/- 11.4 years and 51 healthy volunteers (51 eyes) with a mean age of 45.2 +/- 9.9 years were included in the study. First applanation velocity (A1V) and deformation amplitude (DA) were lower in POAG cases than in other groups. In addition, the stiffness parameter (SP-A1) in the 1st applanation was higher in the POAG group compared to the control and PEG groups.. In glaucoma cases, a positive correlation was found between age and stress strain index, and an inverse relationship between glaucoma duration and SP-A1 Conclusion: The cornea was more resistant to deformation in POAG cases compared to PEG and PG cases and healthy corneas. There was no difference in corneal biomechanics between PEG and PG cases, and between these cases and the control group..
- 1 January 2022
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 47 (1) , 426-435
Open AccessEvaluation of the biomechanical properties of the cornea in different glaucoma types with Corvis Scheimpflug technology
Purpose: The aim of this study was to evaluate the biomechanical properties of the cornea in different types of glaucoma and the relationship between corneal biomechanics and demographic and clinical parameters. Materials and Methods: Primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma (PEG) and pigmentary glaucoma (PG) cases and healthy subjects as a control group were included in this retrospective observational study. Detailed ophthalmological examination was performed, computerized perimetry and optical coherence tomography (OCT) data were recorded in all cases. Corneal biomechanical properties were evaluated with Corvis ST (R) (Oculus, Wetzlar, Germany). Results: Forty-eight glaucoma cases (25 POAG, 15 PEG, 8 PG; 48 eyes) with a mean age of 61.4 +/- 11.4 years and 51 healthy volunteers (51 eyes) with a mean age of 45.2 +/- 9.9 years were included in the study. First applanation velocity (A1V) and deformation amplitude (DA) were lower in POAG cases than in other groups. In addition, the stiffness parameter (SP-A1) in the 1st applanation was higher in the POAG group compared to the control and PEG groups.. In glaucoma cases, a positive correlation was found between age and stress strain index, and an inverse relationship between glaucoma duration and SP-A1 Conclusion: The cornea was more resistant to deformation in POAG cases compared to PEG and PG cases and healthy corneas. There was no difference in corneal biomechanics between PEG and PG cases, and between these cases and the control group..
- Open Access
- 30 December 2021
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 46 (4) , 1409-1418
Penetran keratoplasti endikasyonları: Bir üçüncü basamak sağlık merkezi deneyimi
Amaç: Bu çalışmada bir üçüncü basamak sağlık merkezinde uygulanan penetran keratoplasti (PK) ameliyatlarının endikasyon dağılımının ve çalışma periyodu içerisinde bu dağılımda görülen değişimlerin incelenmesi amaçlanmıştır. Gereç ve Yöntem: PK ameliyatı geçiren hastaların tıbbi kayıtları retrospektif olarak incelendi. Endikasyonlar; korneal skar, korneal distrofi, keratokonus, büllöz keratopati, regreft ve akut enfeksiyöz keratit olmak üzere altı ana kategori altında incelendi. Endikasyonların zaman içerisindeki değişimini inceleyebilmek amacıyla çalışma periyodu iki eşit zaman dilimine ayrıldı ve bu iki periyottaki veriler karşılaştırıldı. Bulgular: İki yüz altmış üç hastanın (117 kadın [%44,5], 146 erkek [%55,5]) 303 gözü çalışmaya dahil edildi. Penetran keratoplastinin en sık endikasyonu korneal skarlar (76 göz, %25,1) idi. Enfeksiyöz keratit sekelleri (38/76, %50) korneal skar etyolojisi içerisinde ilk sırayı alırken, etkenlere göre dağılım incelendiğinde herpetik keratite bağlı sekeller (21/38, %55,2) en büyük alt grubu oluşturmaktaydı. Çalışma periyodunun 2. yarısında korneal distrofi nedeniyle uygulanan cerrahilerin oranının azaldığı, regreft uygulanan olguların oranının ise artış gösterdiği saptandı. Sonuç: Çalışmamızda PK’nın en sık nedeni korneal skar olarak bulunmuştur.. Enfeksiyöz keratit ve korneal travma olguları açısından sağlık hizmetlerinin iyileştirilmesi; korneal distrofiler açısından ise akraba evliliklerinin önlenmesine yönelik sosyal projelerin ve genetik danışmanlık hizmetlerinin yaygınlaştırılması, bölgemizde korneal patolojiler kaynaklı görme kayıplarını azaltabilecektir.
- 30 December 2021
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 46 (4) , 1409-1418
Open AccessPenetran keratoplasti endikasyonları: Bir üçüncü basamak sağlık merkezi deneyimi
Amaç: Bu çalışmada bir üçüncü basamak sağlık merkezinde uygulanan penetran keratoplasti (PK) ameliyatlarının endikasyon dağılımının ve çalışma periyodu içerisinde bu dağılımda görülen değişimlerin incelenmesi amaçlanmıştır. Gereç ve Yöntem: PK ameliyatı geçiren hastaların tıbbi kayıtları retrospektif olarak incelendi. Endikasyonlar; korneal skar, korneal distrofi, keratokonus, büllöz keratopati, regreft ve akut enfeksiyöz keratit olmak üzere altı ana kategori altında incelendi. Endikasyonların zaman içerisindeki değişimini inceleyebilmek amacıyla çalışma periyodu iki eşit zaman dilimine ayrıldı ve bu iki periyottaki veriler karşılaştırıldı. Bulgular: İki yüz altmış üç hastanın (117 kadın [%44,5], 146 erkek [%55,5]) 303 gözü çalışmaya dahil edildi. Penetran keratoplastinin en sık endikasyonu korneal skarlar (76 göz, %25,1) idi. Enfeksiyöz keratit sekelleri (38/76, %50) korneal skar etyolojisi içerisinde ilk sırayı alırken, etkenlere göre dağılım incelendiğinde herpetik keratite bağlı sekeller (21/38, %55,2) en büyük alt grubu oluşturmaktaydı. Çalışma periyodunun 2. yarısında korneal distrofi nedeniyle uygulanan cerrahilerin oranının azaldığı, regreft uygulanan olguların oranının ise artış gösterdiği saptandı. Sonuç: Çalışmamızda PK’nın en sık nedeni korneal skar olarak bulunmuştur.. Enfeksiyöz keratit ve korneal travma olguları açısından sağlık hizmetlerinin iyileştirilmesi; korneal distrofiler açısından ise akraba evliliklerinin önlenmesine yönelik sosyal projelerin ve genetik danışmanlık hizmetlerinin yaygınlaştırılması, bölgemizde korneal patolojiler kaynaklı görme kayıplarını azaltabilecektir.